Polaris Group 2024 Annual Report with Sustainability Disclosures
Company: Polaris Group
Sector: Manufacturing
Country: United States
Year: 2024
Type: Annual Report with Sustainability Disclosures
Pages: 129
The report describes the company's 2024 expansion from new-drug development into peptide drugs, APIs, generics, and CDMO services following the July merger with Genovior Biotech. Group operating income reached NTD107,000,000, entirely attributed to biopharmaceutical CDMO business, while ADI-PEG 20 remained in clinical development. The report also documents a sustainable-development governance structure, material-topic and climate-risk assessments, and use of GRI, SASB, and TCFD references.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.